Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BAT2606 vs Mepolizumab in Healthy Chinese Males
NCT05576454Phase 1Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Sep 2022
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BAT2606 in severe asthma (3 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Concentration-Time Curve From Time Zero to Infinity. Started Sep 2022; status: completed.
02
Drugs
BAT2606
03
Conditions
severe asthma
Beyond the preview
Go deeper on NCT05576454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05576454.